Elmamoun, M.
,
Eraso, M.
Anderson, M.
Maharaj, A.
Coates, L.
Chandran, Vinod
Abogamal, A.
Adebajo, A. O.
Ajibade, A.
Ayanlowo, O.
Azevedo, V.
Bautista-Molano, W.
Carneiro, S.
Goldenstein-Schainberg, C.
Hernandez-Velasco, F.
Ima-Edomwonyi, U.
Lima, A.
Medina-Rosas, J.
Mody, G. M.
Narang, T.
Ortega-Loayza, A. G.
Ranza, R.
Sharma, A.
Toloza, S.
Vega-Espinoza, L.
Vega-Hinojosa, O.
Funding for this research was provided by:
International League of Associations for Rheumatology
Article History
Received: 12 September 2019
Revised: 26 December 2019
Accepted: 6 January 2020
First Online: 16 January 2020
Compliance with ethical standards
: The manuscript does not contain clinical studies or patient data.
: All authors have disclosed any conflicts of interest. The individual declarations are summarized below:V Chandran reports grants and personal fees from Abbvie, personal fees from Amgen, personal fees from Celgene, personal fees from BMS, personal fees and other from Eli Lilly, personal fees from Janssen, personal fees from Novartis, personal fees from Pfizer, personal fees from UCB, outside the submitted work. L Coates has received research grants from Abbvie, Celgene, Novartis, Pfizer and Lilly, Honoraria from Abbvie, Amgen, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB. GM Mody has received honoraria from Astra Zeneca, GlaxoSmithKline and Janssen.